Novartis Ag

University of Pennsylvania

Beth Israel Deaconess Medical Center, Inc.

Novartis Pharma Gmbh

David Jonathan Glass

Joan Mannick

Leon Murphy

Jennifer Brogdon

Michael C Milone

Qilong Wu

Yongqiang Wang

Marco Ruella

Shou-Ih Hu

Carl H June

Andreas Loew

Saar Gill

Hilmar Erhard Ebersbach

Jiquan Zhang

Saad Kenderian

David L Porter

Reshma Singh

Celeste Richardson

Simone Bonazzi

Andrew William Patterson

Huijuan Song

Silvio Roggo

Mara Fornaro

William Raj Sellers

Tea Shavlakadze

Eugene Choi

Heather Huet

Gabriela Plesa

Brian Edward Vash

Jan Weiler

Boris Engels

Brian Walter Granda

Li Zhou

Anthony Rosenzweig

Manuel Mihalic

Lai Wei

Qiumei Yang

Julia Jascur

John Hastewell

Michael Connolly

Jason D Roh

Marcela V Maus

Thomas Huber

Abhishek Garg

John C Byrd

Thomas Jostock

Mariusz Wasik

Natarajan Muthusamy

Avery D Posey

Amy Jo Johnson

Shinji Hatakeyama

Jan J Melenhorst

Holger Laux

Felipe Bedoya

Jason A Dubovsky

Hans Bitter

Elena Orlando

Estelle Trifilieff

Jerome Feige

Sandrine Romand

Michael D Connolly

Patrik Zueger

Corin Dorfmeier

Nicholas Wilcox

Joseph Fraietta

Brian Peter Richardson

Jihyun Lee

Abhishnek Garg

The disclosure provides 32-deoxo-rapamycin derivatives of Formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions and pharmaceutical combinations comprising a compound of Formula (I), and methods of making same. Also provided herein are methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating the diseases and disorders described herein.

Rapamycin derivatives

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

The disclosure relates to compounds of formula (I) and pharmaceutically acceptable salts, and compositions thereof, wherein the substituents are as defined herein. Also provided are methods of making compounds of formula (I), and methods involving the compounds or compositions for treating disorders and diseases described herein.

The disclosure relates to novel uses and methods for preventing and/or treating heart disease, which employ a therapeutically effective amount of an ActRII receptor antagonist, e.g., an ActRII receptor binding molecule, e.g., an ActRII receptor antibody, such as the bimagrumab antibody.

Method of treating structural and/or functional cardiac abnormalities by administering an anti-ActRII receptor antibody

The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.

Treatment of cancer using a CD123 chimeric antigen receptor

Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.

Regulatable chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

Anti-BCMA chimeric antigen receptor

Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody

Cancer biomarkers and methods of using them are disclosed.

Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof

The present invention relates to a combination comprising (a) RAD001, or a pharmaceutically acceptable salt thereof, and (b) BEZ235, or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use for enhancement of an immune response; a pharmaceutical composition comprising such combination; a method of enhancing immune response in a subject comprising administration of said combination to a subject in need thereof; use of such combination for preparation of a medicament for the enhancement of an immune response; and a commercial package thereto.

Pharmaceutical combination of everolimus with dactolisib

The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Treatment of cancer using a CLL-1 chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a kinase inhibitor, e.g., a kinase inhibitor described herein. The invention also provides kits and compositions described herein.

Treatment of cancer using anti-CD19 Chimeric Antigen Receptor

Growing community of inventors

Cambridge, MA, United States of America

David Jonathan Glass